Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy with concomitant Temodal versus neoadjuvant temozolomide followed by radiotherapy with concomitant Temodal in high-grade glioma
ISRCTN45209900Phase 3Completed
- Sponsor
- Nordic Clinical Brain Tumour Study Group
- Start
- Jan 2003
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of temozolomide in anaplastic astrocytoma (AA) and glioblastoma (GBM) (2 arms), sponsored by Nordic Clinical Brain Tumour Study Group. Primary endpoint: Overall survival. Started Jan 2003; status: completed.
02
Drugs
temozolomide
03
Conditions
anaplastic astrocytoma (AA)glioblastoma (GBM)
Beyond the preview
Go deeper on ISRCTN45209900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN45209900.